Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Cutaneous Cholesterol Emboli Treatment & Management

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Jun 22, 2016
 

Medical Care

Medical treatment of CCE has largely been unsuccessful, with the exception of a few anecdotal reports. The early goals of treatment are to augment the circulation and to try to prevent occlusion. Some believe this can be achieved with drugs that inhibit coagulation, platelet aggregation, and RBC sludging. Vasodilators and corticosteroids have also been used. Variable results have been reported with the use of heparin, streptokinase, urokinase, tissue plasminogen activator, warfarin, bishydroxycoumarin, aspirin, pentoxifylline, dipyridamole, prostaglandins, prostacyclin, intra-arterial papaverine, sulfinpyrazone, low–molecular-weight dextran, nifedipine, prednisone, and methylprednisolone. Some have also recently reported success with hemostatic and lipid-lowering agents (eg, vitamin K, carbazochrome, tranexamic acid, reptilase, lovastatin, cholestyramine, probucol).

Although anticoagulants have been observed to cause CCE and many reports indicate the cessation of symptoms upon discontinuation, in 2 patients, heparin resulted in resolution of their myalgias, tenderness, and pregangrene. Furthermore, they did not have any recurrence of symptoms or signs. Another group reported clinical and radiographic improvement following therapy with intra-arterial streptokinase, heparin, and prostacyclin. Iloprost, a prostacyclin analog, has also been reported to improve renal function and peripheral symptoms in patients with CE. Subcutaneous heparin, which is intermittently administered through the tissue to provide trough periods, may allow more effective healing of plaques than the intravenous form.

Some recommend a trial of corticosteroids for their anti-inflammatory effect to limit arteritis and the subsequent fibrotic occlusion of vessels; however, in 9 patients with CCE thought to have vasculitis who were treated with corticosteroids, 7 died.

Lovastatin may effect healing by inducing the regression of atherosclerosis and by decreasing plaque cholesterol content, which is linked to an increased incidence of emboli.

One group used the combination of hemostatic (ie, vitamin K, carbazochrome, tranexamic acid, reptilase) and antihyperlipidemic (ie, cholestyramine, probucol) drugs and had positive results.

The clinical effect of circulator boot therapy in patients with cholesterol embolization syndrome of the lower extremities in patients following cardiac or vascular procedures may be an effective noninvasive therapeutic option.[32]

Next

Surgical Care

Removal of the source of the emboli using thromboendarterectomy or excision and replacement of the prosthesis has resulted in resolution of CCE. Because gangrene is more likely to occur in persons whose circulation is already compromised, reconstruction of the stenotic proximal artery, which may or may not be the source of emboli, is also advised. Other forms of surgical treatment include embolectomy, sympathectomy, and primary excision of necrotic tissue, possibly involving amputation.

Thoracoabdominal repair is the criterion standard of treatment. Bypass without vessel ligation is contraindicated because it does not remove the source of emboli. Improvement and healing of cutaneous lesions was observed in 2 of 3 patients after resection of abdominal aortic aneurysms. Another group reported that 4 of 5 patients with ischemic lesions from toe gangrene or necrosis benefited from arterial reconstruction. For multilevel occlusive disease, proximal reconstructions are performed prior to distal ones, but the reverse may be appropriate for blue toe syndrome.

If the entire aorta is diffusely ulcerative, the source of emboli is inaccessible, or the patient is a poor surgical candidate, then thoracoabdominal repair may not be possible. Palliative treatment for such patients is axillobifemoral bypass with external iliac ligation. Four patients with peripheral emboli who underwent this procedure had cessation of new lesions, healing, and pain relief. Embolization to the pelvic circulation may be controlled by iliac ligation at the aortic bifurcation or by individual interruption of the internal iliac arteries. Another group had similar success with this technique and was able to salvage 12 limbs in 6 patients, apart from the loss of a fifth toe.

Embolectomy may be effective in cases of the larger atheroemboli.

Peripheral nerve blockade or lumbar sympathectomy has been used to deter cutaneous breakdown and promote healing. They are advocated for patients with persistent areas of pain, cyanosis, or cutaneous gangrene in the involved limb. Sympathetic blockade influences the microcirculation of the skin through a direct effect on arteriovenous communications that are almost entirely made of smooth muscle.

If peripheral circulation is intact, hard eschars from infarcted skin and/or muscle on the legs should be excised primarily.

If circulation is inadequate, amputation may be the only way to stop the advance of ascending gangrene.

Previous
Next

Consultations

CE can cause severe dysfunction of practically any organ, but renal emboli resulting in hypertension and renal insufficiency or failure is the most common complication. Management by a nephrologist, with possible referral to a dialysis service, may be necessary.

Previous
Next

Complications

The main complication of CCE is gangrene necessitating extremity amputation. In cases of penile ischemia and necrosis, circumcision and even penectomy has been required. In 73 patients with CCE, amputation was performed in 11 (15%).

Patients with CCE frequently have emboli to other systems and the attendant complications. The most common sites of embolization that result in clinical disease are the renal, cardiac, and gastrointestinal systems. Findings include hypertension, renal failure, myocardial infarction, and a multitude of gastrointestinal disorders, including hemorrhage, ulcers, infarction, obstruction, perforation, and stricture formation.

Death most often results from multiple factors or from renal or cardiac complications.

Previous
Next

Prevention

During aortic surgery, gentle clamping, no reclamping, and minimal handling of the aorta are recommended. Smaller, less rigid catheters and less manipulation of them is important, as is the avoidance of high-pressure injectors. For aortography, consider a transaxillary approach instead of a translumbar approach if aortic plaques are present; however, the transaxillary approach is technically more difficult, with an increased risk of thrombosis, hematoma, and possible brachial plexus injury.

Avoid anticoagulants, which can cause hemorrhage within the walls of sclerotic arteries, with subsequent thrombosis and elevation of an atheromatous plaque.

During aortoiliac reconstruction, the downward flush is a maneuver in which, following the proximal and one distal anastomosis, a gush of blood is allowed to escape through the unanastomosed limb of the prosthesis, while the other artery is clamped, to remove debris. In a variation on this technique, one group was able to prevent peripheral emboli during aortoiliac reconstruction with the placement of a blood filter and perfusion cannula between the unanastomosed limb and unattached distal artery, allowing a larger gush of blood and more atheromatous debris to be flushed out.

Some authorities have suggested that CABG surgery should be contraindicated in patients with a known history of CE.

Previous
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Jerry Rothenberg, MD Clinical Associate Professor, Department of Dermatology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School; President, Director, New Jersey Dermatopathology Laboratory, Inc

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Associate Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

James J Nordlund, MD Professor Emeritus, Department of Dermatology, University of Cincinnati College of Medicine

James J Nordlund, MD is a member of the following medical societies: American Academy of Dermatology, Sigma Xi, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Kenneth A. Becker, MD, to the development and writing of this article.

References
  1. Flory CM. Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Path. 1945. 21:549-65.

  2. Hoye SJ, Teitelbaum S, Gore I, Warren R. Atheromatous embolization; a factor in peripheral gangrene. N Engl J Med. 1959 Jul 16. 261(3):128-31. [Medline].

  3. Lane JE, Lane TN, Shams M, Lane CE. Cutaneous cholesterol embolization. J Am Acad Dermatol. 2009 Apr. 60(4):711-3. [Medline].

  4. Deschamps P, Leroy D, Mandard JC, Heron JF, Lauret P. Livedo reticularis and nodules due to cholesterol embolism in the lower extremities. Br J Dermatol. 1977 Jul. 97(1):93-7. [Medline].

  5. Kalter DC, Rudolph A, McGavran M. Livedo reticularis due to multiple cholesterol emboli. J Am Acad Dermatol. 1985 Aug. 13(2 Pt 1):235-42. [Medline].

  6. Kazmier FJ, Sheps SG, Bernatz PE, Sayre GP. Livedo reticularis and digital infarcts: a syndrome due to cholesterol emboli arising from atheromatous abdominal aortic aneurysms. Vasc Dis. 1966 Feb. 3(1):12-24. [Medline].

  7. Kusaba A, Imayama S, Furue M. Delayed appearance of livedo reticularis in 3 cases with a cholesterol embolism. Arch Dermatol. 1999 Jun. 135(6):725-6. [Medline].

  8. Sheehan MG, Condemi JJ, Rosenfeld SI. Position dependent livedo reticularis in cholesterol emboli syndrome. J Rheumatol. 1993 Nov. 20(11):1973-4. [Medline].

  9. Moolenaar W, Lamers CB. Cholesterol crystal embolization in the Netherlands. Arch Intern Med. 1996 Mar 25. 156(6):653-7. [Medline].

  10. Panniello G, Fenizi G, Amicarelli V, Sanguedolce F, Carosi I, Bisceglia M. Spontaneous cutaneous cholesterol crystal embolism with focal clinical symptomatology: report of a case in an unusual location with secondary histological changes reminiscent of atypical decubital fibroplasia. Am J Dermatopathol. 2011 Oct. 33(7):726-8. [Medline].

  11. Quinones A, Saric M. The cholesterol emboli syndrome in atherosclerosis. Curr Atheroscler Rep. 2013 Apr. 15(4):315. [Medline].

  12. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003 Jul 16. 42(2):211-6. [Medline].

  13. Mooney T, Joseph P. Purple toes syndrome following stroke thrombolysis and warfarin therapy. Intern Med J. 2014 Jan. 44(1):107-8. [Medline].

  14. Duman N, Sahin S. Lesson of the month 1: sudden onset postural livedo reticularis, cyanotic toes and multiorgan failure. Clin Med. 2014 Jun. 14(3):314-5. [Medline].

  15. Ogbechie OA, Morley KW, Sugai D, Nambudiri VE, Senna MM, Hoang MP, et al. Limited cutaneous pseudovasculitis: a mild variant of cholesterol emboli syndrome. Circulation. 2015 Feb 3. 131 (5):514-5. [Medline].

  16. Wanat KA, Kim B, Rosenbach M. Multisystem diseases affecting the skin and eye. Clin Dermatol. 2016 Mar-Apr. 34 (2):214-41. [Medline].

  17. Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol. 1986 Oct. 122(10):1194-8. [Medline].

  18. Aivaz O, Turegano MM, Radfar A. A purpuric patch on the flank. JAMA Dermatol. 2015 Jan. 151 (1):97-8. [Medline].

  19. Tashiro M, Ito K, Saito T. An autopsy case of idiopathic cholesterol embolism. Clin Exp Nephrol. 2013 Feb. 17(1):142-3. [Medline].

  20. Colt HG, Begg RJ, Saporito JJ, Cooper WM, Shapiro AP. Cholesterol emboli after cardiac catheterization. Eight cases and a review of the literature. Medicine (Baltimore). 1988 Nov. 67(6):389-400. [Medline].

  21. Freund NS. Cholesterol emboli syndrome following cardiac catheterization. Postgrad Med. 1990 Apr. 87(5):55-60. [Medline].

  22. Ghahramani GK, Seline AE, Wanat KA. Postprocedural Blue Toes. JAMA. 2016 Apr 5. 315 (13):1396-7. [Medline].

  23. Glassock RJ, Ritz E, Bommer J, Andrassy K, Waldherr R. Acute renal failure, hypertension and skin necrosis in a patient with streptokinase therapy. Am J Nephrol. 1984. 4(3):193-200. [Medline].

  24. Ridker PM, Michel T. Streptokinase therapy and cholesterol embolization. Am J Med. 1989 Sep. 87(3):357-8. [Medline].

  25. Schwartz MW, McDonald GB. Cholesterol embolization syndrome. Occurrence after intravenous streptokinase therapy for myocardial infarction. JAMA. 1987 Oct 9. 258(14):1934-5. [Medline].

  26. Arora RR, Magun AM, Grossman M, Katz J. Cholesterol embolization syndrome after intravenous tissue plasminogen activator for acute myocardial infarction. Am Heart J. 1993 Jul. 126(1):225-8. [Medline].

  27. Bhardwaj M, Goldweit R, Erlebacher J, Kashani M, Levin D, Leber G. Tissue plasminogen activator and cholesterol crystal embolization. Ann Intern Med. 1989 Oct 15. 111(8):687-8. [Medline].

  28. Shapiro LS. Cholesterol embolization after treatment with tissue plasminogen activator. N Engl J Med. 1989 Nov 2. 321(18):1270. [Medline].

  29. Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Dermatopathol. 2007 Feb. 29(1):44-55. [Medline].

  30. Yang YW, Chen CL, Ho WT, Wang KH. Cutaneous reactive angiomatosis associated with cholesterol embolism. J Cutan Pathol. 2010 Jun. 37(6):692-6. [Medline].

  31. Simon R, Berwert L, Burnier M, Teta D. [Severe renal insufficiency secondary to renal cholesterol emboli: therapeutical options revisited]. Rev Med Suisse. 2010 Mar 3. 6(238):432-4, 436-7. [Medline].

  32. Filip JR, Dillon RS. Treatment of end-stage "trash feet" with the end-diastolic pneumatic boot. Angiology. 2008 Apr-May. 59(2):214-9. [Medline].

  33. Kobayashi H, Abe M, Murata Y, Maruyama T, Furukawa T, Oikawa O, et al. Low-density lipoprotein apheresis for corticosteroid-resistant skin lesions caused by cholesterol crystal embolism: a case report and review of the literature. J Artif Organs. 2015 Mar 28. 78 Suppl 6:43-7. [Medline].

 
Previous
Next
 
Chronic leg ulcer due to cutaneous cholesterol emboli on the leg of a 79-year-old woman.
Skin biopsy specimen demonstrating ulceration and an occluded vessel at the right border of the specimen within the fat. Hematoxylin and eosin stain at 22X magnification.
Higher magnification of the same biopsy specimen, demonstrating cholesterol clefts within an occluded arteriole. Hematoxylin and eosin stain at 297X magnification.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.